You searched for "procedures"

5644 results found

Buy Tonosafe directly from Haag-Streit UK

Earlier this year Haag-Streit UK announced that it would no longer be working with NHS supply chain. In order to provide a more flexible and transparent procurement process, products, including Tonosafe disposable prisms, are now being supplied directly to NHS...

A helping hand from Altomed

Your training journey is important and Altomed is here to help you build skills with confidence. That’s why, for a short time only, we’re offering a Buy 2, Get 1 Free promotion on 4 SimulEYE models (see website for full...

Altomed is thrilled to announce the sponsorship of its 2nd Guide Dog puppy Geordie!

Named in tribute to Altomed’s Northeast roots, Geordie is a striking black German Shepherd, confident, clever, and full of character. His unique breed makes him extra special within the Guide Dogs community. Geordie follows in the pawprints of Altomed’s first...

Raphaél Ervinckx joins Glaukos

Glaukos Corporation has appointed Raphaél Ervinckx as Vice President and General Manager for the EMEAI region, marking a strategic move to support the company’s continued international growth. Raphaël Ervinckx brings extensive experience in the ophthalmology sector, most recently serving as...

Graham Popham joins Glaukos as Senior Director, Market Access EMEAI

Glaukos are delighted to announce the appointment of Graham Popham as Senior Director, Market Access EMEAI. Graham comments: "’I'm excited to join Glaukos at such a pivotal time in the evolution of ophthalmic care and growth of the organisation. Throughout...

Outline of clinical care for healthy newborns with uncomplicated conjunctivitis in the US

The purpose of this study was to explore the current state of clinical care for healthy newborns with uncomplicated ophthalmia neonatorum (ON) using a large electronic health record dataset. Despite the existence of national guidelines for antepartum screening for N....

Heidelberg Engineering joins the Collaborative Community on Ophthalmic Innovation (CCOI) through EssilorLuxottica’s Vision Architect membership

Heidelberg Engineering announced that it is joining the Collaborative Community on Ophthalmic Innovation (CCOI) as part of its parent company EssilorLuxottica’s Vision Architect membership – CCOI’s highest level of industry participation. CCOI is a public–private forum that convenes patients, clinicians,...

Mainline Instruments at 100%

Visit Mainline Instruments at STAND J20 during 100% Optical 2026 for an exciting programme of interactive workshops and expert-led lectures on the latest eye care innovations. Highlights include Ultra-Widefield Confocal Imaging, Dry Eye assessment, Tomography, and more. Don’t miss our...

Prism adaptation responses for variable distance-near deviation in intermittent exotropia

The purpose of this study was to evaluate the effect of the prism adaptation test (PAT) on angle and distance-near-deviation (DND) in intermittent exotropia (IXT), and determine the frequency of responders and non-responders to PAT. This was a single-centre study...

Sight Sciences Supports Royal College of Ophthalmologists MIGS Course.

Sight Sciences were pleased to take part in the inaugural Minimally Invasive Glaucoma Surgery (MIGS) course at the Royal College of Ophthalmologists in London on 16 January. Organised by Mr. Ahmad Elsahn, the event brought together renowned glaucoma specialists from...

How does presentation, progression and outcome of new onset diplopia vary between older and younger adults?

The authors present a retrospective case review with the aim of comparing the frequency of different causes for new onset binocular diplopia in 2 age groups, above and below 65 years old. Adult patients with new onset diplopia within a...

Clinical outcomes following intraluminal stent removal from the PAUL glaucoma implant

This single German centre retrospective cohort study included 70 eyes from 68 patients. Qualified and complete success rates (95% CI) were 92.9% and 55.7% after 1 year and 88.6% (81.4–95.7%) and 50% (37.1–62.9%) at the last follow-up time point for...